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Background: Preoperative and hospital-acquired anaemia is common among surgical patients. It is associated with
an increased risk of morbidity and mortality and a strong risk factor for allogeneic blood transfusions with their own
inherent risks. Patient Blood Management (PBM) concepts aim to increase and preserve autologous erythrocyte
volume and to optimise haemotherapy. They thus have great potential to benefit patients.
Methods/Design: This prospective, multi-centre clinical trial tests the hypothesis that PBM programs are safe
and effective in the care of adult surgical patients. Primary outcome is a composite endpoint of adverse events
and in-hospital mortality.
Discussion: This trial will determine whether the implementation of a PBM program is safe and effective in
terms of clinical outcome compared to a pre-implementation cohort. This trial is registered at www.clinicaltrials.
gov (NCT01820949).
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Anaemia has a high prevalence among surgical patients as
it is often preexisting, acquired and/or exacerbated during
hospital stay [1,2]. It is associated with higher risks of
morbidity and mortality and is also a major risk factor for
allogeneic blood transfusions. The transfusion of allogen-
eic red blood cell (RBC) units is by itself also associated
with increased morbidity and mortality due to infectious,
immunological, pulmonary and thromboembolic compli-
cations [3-5]. Surely, adequate RBC transfusion is a life-
saving medical intervention for those in need of it, but
transfusion practice varies significantly when comparing
hospitals and physicians, which implies that insecurity* Correspondence: dania.fischer@kgu.de
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article, unless otherwise stated.regarding adequate utilisation exists [6,7]. Additionally,
serious blood supply challenges are imminent due to
changing population demographics. Therefore, modifiable
risk factors for transfusion such as anaemia should be
targeted and a rational use of RBC units and safe
clinical transfusion practice is mandatory. The World
Health Organisation encourages all member states to
implement Patient Blood Management (PBM) programs
employing multiple combined strategies to increase and pre-
serve autologous erythrocyte volume in order to minimise
unnecessary exposure to RBC transfusions [8]. Early detec-
tion and appropriate treatment of anaemia, multidisciplinary
concepts designed to maintain haemoglobin concentration,
to optimise haemostasis, and to minimise blood loss shall
be thrived for in an effort to improve patient outcome and
ensure adequate use of scarce resources [9,10].
Several public-based PBM initiatives are in progress, e.g. in
Australia, to optimise utilisation of RBC concentrates [8,11].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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entific data in terms of safety issues. Thus, a large study with
robust and relevant clinical endpoints is required. The object
of this study is to demonstrate that the implementation of a
PBM program is safe.Methods
Trial design
This is a prospective multi-centre controlled epidemiologic
non-inferiority trial with an approximated population of
100,000 patients undergoing surgical procedures. A
patient-focused and evidence-based PBM program has
been implemented in four German University Hospi-
tals. Different time slots for control, implementation and
study phases according to a non-randomised stepped
wedge trial design were allocated for control, implementa-
tion and intervention periods.Participants
Four German university hospitals are participating in the
study: Frankfurt, Bonn, Kiel, Muenster. The PBM program
includes all patients undergoing surgical procedures
ranging anywhere from: orthopaedic and visceral sur-
gery, general surgery, cardiothoracic surgery, trauma,
otorhinolaryngology, gynecology and obstetrics, ur-
ology, oral and maxillofacial surgery, vascular surgery,
and neurosurgery to increase applicability of the evidence
obtained during this trial. Exclusion criteria are: <18 years,
ophthalmologic or dermatologic or outpatient surgery. If a
patient has multiple hospital admissions during the study
period, the first hospital stay will be analysed.Figure 1 Algorithm for the detection, evaluation and management ofThe control group will be composed of the patients
treated according to the standard protocol in charge be-
fore implementation of the PBM program. A period of
three months was allowed for the implementation of the
PBM components. Patients treated after implementation
will be allocated to the PBM cohort until July 2015.Management
For consistent implementation regular teaching sessions
were held at the beginning of the program and are re-
peated every six months. The focus is on clinical prac-
tice, outcome and safety issues in order to increase
knowledge on PBM and awareness of the clinical impli-
cations of anaemia and the need for alternatives to
transfusion. The new program is additionally promoted
through hand outs, posters, checklists and web-based in-
formation among health care providers and patients.
Our PBM program has three main pillars:
a) Preoperative optimisation of haemoglobin levels:
The preoperative detection, evaluation and therapy of
anaemia diagnosis and treatment focuses specifically on
those patients (aged 18 years and older) scheduled for
elective surgery. Figure 1 shows the work-flow used at
the University Hospital Frankfurt. Surgeries associated
with a risk for transfusion >10% were identified by retro-
spective analysis of hospital data from 2011 with the
hospital-information system Agfa ORBIS. Patients sched-
uled for elective surgery falling in that spectrum are
screened and treated at the earliest possibility accordinganaemia at the University Hospital Frankfurt.
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postponed for at least four days (Figure 1) [12]. Iron defi-
ciency anaemia (IDA) is treated with intravenous iron.
Anaemic patients are suggested to be scheduled for both
haematological and/or gastroenterological consultations
for further diagnostics and optimal treatment of anaemia
in cases where iron deficiency anaemia is unlikely.
b) Standardisation of transfusion practice according
to evidence-based guidelines:
Lectures on transfusion triggers according to the Cross-
Sectional Guidelines for Therapy with Blood Components
and Plasma Derivatives of the German Medical Asso-
ciation [13]. The strict enforcement of guideline-based
transfusion triggers for surgical patients is supported by
checklists attached to each RBC and/or during electronic
documentation of the indication for RBC in patient’s
record (Figure 2) and during the perioperative process
(Figure 3).
c) Alternatives to transfusion, and blood-sparing
techniques:
This part of the PBM program comprises a broad use of
the cell saver system in defined subgroups of patients,
temperature management, point-of-care diagnostics,Figure 2 Transfusion trigger checklist.optimised coagulation management, and restrictive blood
sampling [14].
In support of the strategies above, a PBM Checklist
was introduced to guide physicians through the peri-
operative process (Figure 3).
Endpoints
Primary efficacy endpoint
Primary endpoints are the following composite end-
points: in-hospital myocardial infarction, stroke, acute
renal failure, death of any cause, pneumonia and sepsis
until discharge from hospital in patients before and
after implementation of PBM program.
Secondary endpoints
 Length of stay on the intensive care unit
 Total hospital stay
 Quantitative utilisation of allogeneic RBC units,
platelet concentrates, other blood products
Data recording
The efficacy endpoints will be monitored by means of
the hospital-information system Agfa ORBIS, where the
relevant diagnoses are encoded based on the ICD-10
system. All patient-related data will be analysed elec-
tronically and anonymised. The follow-up will last until
discharge from the hospital.
Ethics
The PBM program is in accordance with state of the art
transfusion guidelines and current recommendations for
preoperative haemoglobin optimisation. This prospective
multi-centre controlled epidemiologic trial (non-inferiority)
has been approved by the ethics committees of the Univer-
sity Hospital Frankfurt (Ref.: 380/12) and of all participating
centers. Data collection is performed anonymously. All col-
lected data will be kept confidential. This study will be per-
formed in accordance with the revision of the Declaration
of Helsinki (2013) [15]. Since implementation will affect all
hospitalised patients, information and informed consent of
individual patients will not be obtained.
Statistics
Sample size and power calculation
According to preliminary data, the composite endpoint
has an approximate incidence of 10%. A difference of 0,5%
is set as the non-inferiority margin as this can be seen as
the natural standard deviation. The level of significance of
non-inferiority is determined be α = 2.5%. This is consist-
ent with a two-sided 95% confidence range of 1 + α = 95%
for the difference in the composite endpoint. A power of
1 + β = 80% is sought. As the number of patients treated
in each of the four university hospitals vary, an exact
Figure 3 Perioperative patient blood management checklist.
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ever, we expect approximately 100,000 participating
patients.
Statistical analysis
The primary aim is to prove non-inferiority of the inter-
vention (PBM) cohort when compared with the control
cohort stratified by center. The primary composite end-
point will be registered electronically by analysis of ICD-
10 diagnoses and will be exported to a data base. It will
be analysed with a one-sided Mantel-Haenszel test with
significance level of α =2.5% for the odds ratio resulting
in H0: OR ≥OR* vs. H1 OR <OR* with OR* being de-
rived from the incidence in the control cohort and an
incidence rate of the PBM cohort which is increased by
the non-inferiority margin of 0.5%. As secondary ana-
lysis, we will analyse two-sided 95% confidence interval
for the difference in the frequency of the composite
safety endpoint as well as for the odds ratios and the sin-
gle components of the composite endpoint. Additionally,
the influence of covariates, e.g. the calendar year, con-
comitant diseases, the asynchrony of the study periods
at different sites will be assessed statistically. Should
there be a significant influence on the incidence of the
composite endpoint, the Mantel-Haenszel test will be
supplemented with a respective multivariate approach
accounting for covariates.
Secondary endpoints will be compared with a two-sided
Wilcoxon-Mann–Whitney test using a significance level of
α =5%. A subgroup analysis will assess if there is some bias
from not excluding patients with multiple hospital stays for
surgical intervention during the study period. A furthersubgroup analysis will assess if there is a difference of safety
between a) elective patients who will receive preoperative
haemoglobin optimisation compared to b) anemic patients
who will not undergo preoperative haemoglobin optimisa-
tion due to failed postponement of surgery in case of surgi-
cal urgency or non-elective surgery, respectively.
Economic evaluation
A cost-utility analysis is being conducted. Resource use
data such as blood products transfused, inpatient days by
ward type, surgery, medications, complications and their
treatment has been integrated into the statistical analysis.
The average cost in each group will be calculated, and from
this the incremental cost-effectiveness ratio will be derived.
Clinical study monitoring
An Independent Data Monitoring and Safety Committee
will analyse the data on a regular basis. If the implementa-
tion of the PBM program will result in a 5% rise of the pri-
mary efficacy endpoint compared to the control cohort
encompassing all recruited patients from all centers, the
IDMC can recommend early termination of the study.
Final decision for early termination will be done by the
principle investigators.
Discussion
While transfusion of cellular blood components is a life-
saving intervention, over-transfusion can be associated
with short and long-term hazards. Therefore risks and
benefits of transfusions should be weighed individually in
every patient and modifiable risk factors for transfusion
such as anaemia should be prevented and treated
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program could help to save a scarce resource and to im-
prove patient outcome and safety [18,19]. In the last ten
years, different aspects of a PBM program have been im-
plemented into clinical practice reducing the utilisation of
allogeneic red blood cell transfusions and improved
outcome [20-24].
Nonetheless, there remains uncertainty about the safety
and effectiveness of PBM. Both fear of insufficient tissue
oxygenation following a restrictive transfusion trigger and
delay of surgery due to preoperative optimisation are the
main concerns prevailing.
This study aims to investigate whether or not a PBM
program is non-inferior in terms of patient outcome
compared to a pre-implementation cohort. The accept-
ance of the PBM program among physicians will deter-
mine the success of this study.
In conclusion, this prospective, multi-centre trial in-
tends to determine whether or not the implementation
of a PBM program is safe and effective in about 100.000
hospitalised patients undergoing surgery.
Trial status and conclusion
This trial is registered at www.clinicaltrials.gov (Identifier:
NCT01820949).
The Patient Blood Management program has been im-
plemented in the four university hospitals of Frankfurt,
Bonn, Kiel and Muenster.
Despite the complex nature of implementing new clin-
ical standards, this trial has proceeded successfully. The
experience and data from this study should help to design
and implement fitting PBM programs in other hospitals.
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